GENEART: Applied Biosystems Deutschland GmbH holds 95% of GENEART Shares

Geneart AG / GENEART: Applied Biosystems Deutschland GmbH holds 95% of GENEART Shares processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Regensburg, August 3, 2010 - The majority shareholder of GENEART AG, Regensburg, Applied Biosystems Deutschland GmbH, Darmstadt ("ABD"), directly holds more than 95% of all shares in GENEART AG as noticed by ABD. ABD informed the management board of GENEART AG about this fact by letter dated August/3/2010. By virtue of this letter ABD also requested that the general meeting of GENEART AG may resolve upon the transfer of shares of the minority shareholders to ABD against payment of an adequate cash consideration (Section 327a para. 1 sentence 1 German Stock Corporation Act, Aktiengesetz, "AktG", so-called Squeeze-Out). The management board of GENEART AG intends to comply with this request and to convene an extraordinary general meeting. This meeting will presumably take place at a time in the last quarter of 2010. GENEART and ABD still intend to conclude a domination agreement (Section 291 et seq. AktG) with GENEART AG as dominated and ABD as dominating entity. The domination agreement shall be submitted for approval to this extraordinary general meeting. For further inquiries, please contact: Dr. Karoline Stürmer GENEART AG Josef-Engert-Str. 11 93053 Regensburg Germany Phone: +49-(0)941-942 76-417 Fax: +49-(0)941-942 76-711 Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49-(0)89-8896906-10 Fax: +49-(0)89-8896906-66 Legal Information: This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results. About GENEART AG: In 2000 GENEART entered the Gene Synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. GENEART's service portfolio ranges from the optimization and production of synthetic genes according to DIN EN ISO 9001:2008, to the generation of gene variants or complex gene libraries and the production of cell lines, to the development and production of DNA and protein based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about 180 people. The company is listed on the German Stock Exchange since May 2006. Since April 2010, U.S.- based Life Technologies Corporation, one of the leading biotechnology companies worldwide with 2009 revenues of USD 3.3B and about 9,000 employees, is the majority shareholder of GENEART AG. [HUG#1435548] --- End of Message --- Geneart AG Josef-Engert-Str.11 Regensburg Germany Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Open Market (Freiverkehr) in Frankfurter Wertpapierbörse; GENEART: This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction for further distribution is prohibited. Source: Geneart AG via Thomson Reuters ONE